

# Heart Failure: Accurate Phenotype Coding

Chanel Opoku-Acheampong | Clinical Pharmacist | Enfield Care Network



## Aim

To improve the accuracy of coding of heart failure diagnosis on a heart failure register within a deprived area.

## Method


- Data extraction – EMIS case list downloaded for stratification
- Desktop review – review of notes, previous consultations, clinic letters, ECHO reports
- Discussion at multidisciplinary team meeting – confirm diagnosis, refer to secondary care if appropriate, optimise medications
- Adjust code on EMIS

## Summary of Results

37 people on the heart failure register:

- 14 had the correct coding;
- 1 inactive person
- 22 patients subsequently coded with the appropriate heart failure phenotype on the heart failure register.
- Accuracy of coding increased from 38% to 97%.

Heart Failure Patients with accurate phenotype coding



## Sustaining the Change

- Regular Audits: Quarterly reviews of the heart failure register to ensure coding is updated with phenotype information.
- Training & Awareness: Provide ongoing education for clinicians and administrative staff on accurate coding and documentation.
- Dashboard: Implement a simple dashboard to track coding accuracy and flag discrepancies which would be reviewed and updated by the practice pharmacy team.

## Learnings

- Regular audits and training session on coding are essential to maintain accuracy.
- Engaging clinicians and coding teams early helped clarify diagnostic criteria and coding standards.

### Staff feedback

*"This project helped improve patient reviews and management. The collaboration of the clinical and administrative team going forward will be integral to its ongoing success."*

### Contact Details

@UCLPartners

@UCLPartners

@UCLPartners

uclpartners.com

**UCLPartners**  
Health Innovation

novo nordisk®

Boehringer  
Ingelheim

Daiichi-Sankyo

UCLPartners CVD Academy is being part funded by sponsorship from Boehringer Ingelheim, Novo Nordisk & Daiichi Sankyo. Boehringer Ingelheim, Novo Nordisk & Daiichi Sankyo have had no input or influence into the arrangements, creation of the content or selection of delegate or faculty members associated with this programme.